Exploitation of pleiotropic actions of statins by using tumour-targeted delivery systems

References

• Afergan E, Ben David M, Epstein H, Koroukhov N, Gilhar D, Rohekar K, Danenberg HD, Golomb G. Liposomal simvastatin attenuates neointimal hyperplasia in rats. AAPS J, 2010;12(2):181–7
   PubMed Web of Science ®Google Scholar
• Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res, 1999;5(8):2223–9
   PubMed Web of Science ®Google Scholar
• Ahtul PV. Preparation and characterization of simvastatin nanosuspension by homogenization method. Int J Pharm Tech Res, 2013;5(1):193–7
   Google Scholar
• Al-Haidari AA, Syk I, Thorlacius H. HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation. Biochem Biophys Res Commun, 2014;446(1):68–72
   PubMed Web of Science ®Google Scholar
• Ali-Boucetta H, Al-Jamal KT, McCarthy D, Prato M, Bianco A, Kostarelos K. Multiwalled carbon nanotube-doxorubicin supramolecular complexes for cancer therapeutics. Chem Commun (Camb), 2008;4:459–61
   PubMed Web of Science ®Google Scholar
• Ali H, Shirode AB, Sylvester PW, Nazzal S. Preparation, characterization, and anticancer effects of simvastatin-tocotrienol lipid nanoparticles. Int J Pharm, 2010;389(1–2):223–31
   PubMed Web of Science ®Google Scholar
• Allavena P, Mantovani A. Immunology in the clinic review series; focus on cancer: Tumour-associated macrophages: Undisputed stars of the inflammatory tumour microenvironment. Clin Exp Immunol, 2012;167(2):195–205
   PubMed Web of Science ®Google Scholar
• Altwairgi AK. Statins are potential anticancerous agents (review). Oncol Rep, 2015;33(3):1019–39
   PubMed Web of Science ®Google Scholar
• Alupei MC, Licarete E, Cristian FB, Banciu M. Cytotoxicity of lipophilic statins depends on their combined actions on HIF-1alpha expression and redox status in B16.F10 melanoma cells. Anticancer Drugs, 2014;25(4):393–405
   PubMed Web of Science ®Google Scholar
• Alupei MC, Licarete E, Patras L, Banciu M. Liposomal simvastatin inhibits tumor growth via targeting tumor-associated macrophages-mediated oxidative stress. Cancer Lett, 2015;356(2 Pt B):946–52
   PubMed Web of Science ®Google Scholar
• Anwar M, Warsi MH, Mallick N, Akhter S, Gahoi S, Jain GK, Talegaonkar S, Ahmad FJ, Khar RK. Enhanced bioavailability of nano-sized chitosan-atorvastatin conjugate after oral administration to rats. Eur J Pharm Sci, 2011;44(3):241–9
   PubMed Web of Science ®Google Scholar
• Arca M, Pigna G. Treating statin-intolerant patients. Diabetes Metab Syndr Obes, 2011;4:155–66
   PubMedGoogle Scholar
• Arias JL. Drug targeting strategies in cancer treatment: An overview. Mini Rev Med Chem, 2011;11(1):1–17
   PubMed Web of Science ®Google Scholar
• Arunkumar N, Deecaraman M, Rani C, Mohanraj KP, Kumar KV. Preparation and solid state characterization of atorvastatin nanosuspension for enhanced solubility and dissolution. Int J PharmTech Res, 2009;1(4):1725–30
   Google Scholar
• Aso S, Ise H, Takahashi M, Kobayashi S, Morimoto H, Izawa A, Goto M, Ikeda U. Effective uptake of N-acetylglucosamine-conjugated liposomes by cardiomyocytes in vitro. J Control Release, 2007;122(2):189–98
   Google Scholar
• Athul PV. Preparation and characterization of simvastatin nanosuspension by homogenization method. Int J PharmTech Res, 2013;5(1):193–7
   Google Scholar
• Aznar S, Lacal JC. Rho signals to cell growth and apoptosis. Cancer Lett, 2001;165(1):1–10
   PubMed Web of Science ®Google Scholar
• Banciu M, Fens MH, Storm G, Schiffelers RM. Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice. J Control Release, 2008;127(2):131–6
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer, 2003;3(6):401–10
   PubMed Web of Science ®Google Scholar
• Borowiak-Palen E, Skupin P, Kruszynska M, Sobotta L, Mielcarek J. Carbon nanotubes linked with pitavastatin: Synthesis and characterisation. J Mater Sci Mater Med, 2011;22(4):845–51
   PubMed Web of Science ®Google Scholar
• Bos JL. ras oncogenes in human cancer: A review. Cancer Res, 1989;49(17):4682–9
   PubMed Web of Science ®Google Scholar
• Brown AJ. Cholesterol, statins and cancer. Clin Exp Pharmacol Physiol, 2007;34(3):135–41
   PubMed Web of Science ®Google Scholar
• Bryan BA, D'Amore PA. What tangled webs they weave: Rho-GTPase control of angiogenesis. Cell Mol Life Sci, 2007;64(16):2053–65
   PubMed Web of Science ®Google Scholar
• Cafforio P, Dammacco F, Gernone A, Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis, 2005;26(5):883–91
   PubMed Web of Science ®Google Scholar
• Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, et al. Breast cancer growth prevention by statins. Cancer Res, 2006;66(17):8707–14
   PubMed Web of Science ®Google Scholar
• Celec P, Behuliak M. The lack of non-steroid isoprenoids causes oxidative stress in patients with mevalonic aciduria. Med Hypotheses, 2008;70(5):938–40
   PubMed Web of Science ®Google Scholar
• Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer, 2002;2(8):563–72
   PubMed Web of Science ®Google Scholar
• Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res, 2003;9(1):10–19
   PubMed Web of Science ®Google Scholar
• Chang CC, Ho SC, Chiu HF, Yang CY. Statins increase the risk of prostate cancer: A population-based case-control study. Prostate, 2011;71(16):1818–24
   PubMed Web of Science ®Google Scholar
• Chang PC, Chung MC, Lei C, Chong LY, Wang CH. Biocompatibility of PDGF-simvastatin double-walled PLGA (PDLLA) microspheres for dentoalveolar regeneration: A preliminary study. J Biomed Mater Res A, 2012;100(11):2970–8
   PubMed Web of Science ®Google Scholar
• Chapman-Shimshoni D, Yuklea M, Radnay J, Shapiro H, Lishner M. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol, 2003;31(9):779–83
   PubMed Web of Science ®Google Scholar
• Chen CC, Tsai TH, Huang ZR, Fang JY. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: Physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm, 2010;74(3):474–82
   PubMed Web of Science ®Google Scholar
• Chen J, Liu B, Yuan J, Yang J, Zhang J, An Y, Tie L, Pan Y, Li X. Atorvastatin reduces vascular endothelial growth factor (VEGF) expression in human non-small cell lung carcinomas (NSCLCs) via inhibition of reactive oxygen species (ROS) production. Mol Oncol, 2012;6(1):62–72
   PubMed Web of Science ®Google Scholar
• Chen L, Nakano K, Kimura S, Matoba T, Iwata E, Miyagawa M, Tsujimoto H, Nagaoka K, Kishimoto J, Sunagawa K, Egashira K. Nanoparticle-mediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension, 2011;57(2):343–50
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang S, Peng G, Yu J, Liu T, Meng R, Li Z, Zhao Y, Wu G. Endothelial NO synthase and reactive oxygen species mediated effect of simvastatin on vessel structure and function: Pleiotropic and dose-dependent effect on tumor vascular stabilization. Int J Oncol, 2013;42(4):1325–36
   PubMed Web of Science ®Google Scholar
• Clendening JW, Pandyra A, Li Z, Boutros PC, Martirosyan A, Lehner R, Jurisica I, Trudel S, Penn LZ. Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. Blood, 2010;115(23):4787–97
   PubMed Web of Science ®Google Scholar
• Coimbra M, Banciu M, Fens MH, de Smet L, Cabaj M, Metselaar JM, Storm G, Schiffelers RM. Liposomal pravastatin inhibits tumor growth by targeting cancer-related inflammation. J Control Release, 2010;148(3):303–10
   PubMed Web of Science ®Google Scholar
• Coleman ML, Olson MF. Rho GTPase signalling pathways in the morphological changes associated with apoptosis. Cell Death Differ, 2002;9(5):493–504
   PubMed Web of Science ®Google Scholar
• Collisson EA, Kleer C, Wu M, De A, Gambhir SS, Merajver SD, Kolodney MS. Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther, 2003;2(10):941–8
   PubMed Web of Science ®Google Scholar
• Crescencio ME, Rodriguez E, Paez A, Masso FA, Montano LF, Lopez-Marure R. Statins inhibit the proliferation and induce cell death of human papilloma virus positive and negative cervical cancer cells. Int J Biomed Sci, 2009;5(4):411–20
   PubMedGoogle Scholar
• Crick DC, Andres DA, Danesi R, Macchia M, Waechter CJ. Geranylgeraniol overcomes the block of cell proliferation by lovastatin in C6 glioma cells. J Neurochem, 1998;70(6):2397–405
   PubMed Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release, 2012;161(2):505–22
   PubMed Web of Science ®Google Scholar
• Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation, 2004;109(23 Suppl 1):III39–43
   PubMed Web of Science ®Google Scholar
• Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer, 2005;5(12):930–42
   PubMed Web of Science ®Google Scholar
• Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, Soria J, Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: An in vitro study. Carcinogenesis, 2001;22(8):1139–48
   PubMed Web of Science ®Google Scholar
• Di Stasi SL, MacLeod TD, Winters JD, Binder-Macleod SA. Effects of statins on skeletal muscle: A perspective for physical therapists. Phys Ther, 2010;90(10):1530–42
   PubMed Web of Science ®Google Scholar
• Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, Nilsson J, Pachinger O, Weidinger F. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 2003;23(1):58–63
   PubMed Web of Science ®Google Scholar
• Dimitroulakos J, Nohynek D, Backway KL, Hedley DW, Yeger H, Freedman MH, Minden MD, Penn LZ. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach. Blood, 1999;93(4):1308–18
   PubMed Web of Science ®Google Scholar
• Dulak J, Jozkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: Relevance to anti-cancer therapy. Curr Cancer Drug Targets, 2005;5(8):579–94
   PubMed Web of Science ®Google Scholar
• Duncan RE, El-Sohemy A, Archer MC. Statins and cancer development. Cancer Epidemiol Biomarkers Prev, 2005;14(8):1897–8
   PubMed Web of Science ®Google Scholar
• Duncan RE, El-Sohemy A, Archer MC. Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. J Biol Chem, 2004;279(32):33079–84
   PubMed Web of Science ®Google Scholar
• Elewa HF, El-Remessy AB, Somanath PR, Fagan SC. Diverse effects of statins on angiogenesis: New therapeutic avenues. Pharmacotherapy, 2010;30(2):169–76
   PubMed Web of Science ®Google Scholar
• Escobar C, Echarri R, Barrios V. Relative safety profiles of high dose statin regimens. Vasc Health Risk Manag, 2008;4(3):525–33
   PubMedGoogle Scholar
• Fang Z, Tang Y, Fang J, Zhou Z, Xing Z, Guo Z, Guo X, Wang W, Jiao W, Xu Z, Liu Z. Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PLoS One, 2013;8(5):e62823
   PubMed Web of Science ®Google Scholar
• Farina HG, Bublik DR, Alonso DF, Gomez DE. Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin Exp Metastasis, 2002;19(6):551–9
   PubMed Web of Science ®Google Scholar
• Favero GM, Otuki MF, Oliveira KA, Bohatch MS, Jr, Borelli P, Barros FE, Maria DA, Fernandes D, Bydlowski SP. Simvastatin impairs murine melanoma growth. Lipids Health Dis, 2010;9:142
   PubMed Web of Science ®Google Scholar
• Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer, 2007;121(11):2381–6
   PubMed Web of Science ®Google Scholar
• Feleszko W, Balkowiec EZ, Sieberth E, Marczak M, Dabrowska A, Giermasz A, Czajka A, Jakobisiak M. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer, 1999;81(4):560–7
   PubMed Web of Science ®Google Scholar
• Fernandez AM, Van Derpoorten K, Dasnois L, Lebtahi K, Dubois V, Lobl TJ, Gangwar S, Oliyai C, Lewis ER, Shochat D, Trouet A. N-Succinyl-(beta-alanyl-L-leucyl-L-alanyl-L-leucyl)doxorubicin: An extracellularly tumor-activated prodrug devoid of intravenous acute toxicity. J Med Chem, 2001;44(22):3750–3
   PubMed Web of Science ®Google Scholar
• Fiaschi T, Chiarugi P. Oxidative stress, tumor microenvironment, and metabolic reprogramming: A diabolic liaison. Int J Cell Biol, 2012;2012:762825
   PubMedGoogle Scholar
• Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med, 1995a;333(26):1757–63
   Google Scholar
• Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med, 1971;285(21):1182–6
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med, 1995b;1(1):27–31
   PubMed Web of Science ®Google Scholar
• Franzoni F, Quinones-Galvan A, Regoli F, Ferrannini E, Galetta F. A comparative study of the in vitro antioxidant activity of statins. Int J Cardiol, 2003;90(2–3):317–21
   PubMed Web of Science ®Google Scholar
• Frick M, Dulak J, Cisowski J, Jozkowicz A, Zwick R, Alber H, Dichtl W, Schwarzacher SP, Pachinger O, Weidinger F. Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells. Atherosclerosis, 2003;170(2):229–36
   PubMed Web of Science ®Google Scholar
• Friis S, Olsen JH. Statin use and cancer risk: An epidemiologic review. Cancer Invest, 2006;24(4):413–24
   PubMed Web of Science ®Google Scholar
• Fromigue O, Hamidouche Z, Marie PJ. Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem, 2008;283(45):30549–56
   PubMed Web of Science ®Google Scholar
• Fromigue O, Hay E, Modrowski D, Bouvet S, Jacquel A, Auberger P, Marie PJ. RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ, 2006;13(11):1845–56
   PubMed Web of Science ®Google Scholar
• Garcia-Ruiz C, Morales A, Fernandez-Checa JC. Statins and protein prenylation in cancer cell biology and therapy. Anticancer Agents Med Chem, 2012;12(4):303–15
   PubMed Web of Science ®Google Scholar
• Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, Santoro A, Laezza C, Bifulco M. Pharmacological actions of statins: A critical appraisal in the management of cancer. Pharmacol Rev, 2012;64(1):102–46
   PubMed Web of Science ®Google Scholar
• Gbelcova H, Lenicek M, Zelenka J, Knejzlik Z, Dvorakova G, Zadinova M, Pouckova P, Kudla M, Balaz P, Ruml T, Vitek L. Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer, 2008;122(6):1214–21
   PubMed Web of Science ®Google Scholar
• Ghaisas MM, Dandawate PR, Zawar SA, Ahire YS, Gandhi SP. Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models. Inflammopharmacology, 2010;18(4):169–77
   PubMedGoogle Scholar
• Gingras D, Lamy S, Beliveau R. Tyrosine phosphorylation of the vascular endothelial-growth-factor receptor-2 (VEGFR-2) is modulated by Rho proteins. Biochem J, 2000;348(Pt 2):273–80
   PubMed Web of Science ®Google Scholar
• Gliemroth J, Zulewski H, Arnold H, Terzis AJ. Migration, proliferation, and invasion of human glioma cells following treatment with simvastatin. Neurosurg Rev, 2003;26(2):117–24
   PubMed Web of Science ®Google Scholar
• Glynn SA, O'Sullivan D, Eustace AJ, Clynes M, O'Donovan N. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. BMC Cancer, 2008;8:9
   PubMed Web of Science ®Google Scholar
• Gniadecki R. Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem Biophys Res Commun, 2004;320(1):165–9
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature, 1990;343(6257):425–30
   PubMed Web of Science ®Google Scholar
• Gopalan A, Yu W, Sanders BG, Kline K. Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway. Cancer Lett, 2012;329(1):9–16
   PubMed Web of Science ®Google Scholar
• Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev, 2004;30(7):609–41
   PubMed Web of Science ®Google Scholar
• Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: From protein prenylation to immunomodulation. Nat Rev Immunol, 2006;6(5):358–70
   PubMed Web of Science ®Google Scholar
• Gregg D, Rauscher FM, Goldschmidt-Clermont PJ. Rac regulates cardiovascular superoxide through diverse molecular interactions: More than a binary GTP switch. Am J Physiol Cell Physiol, 2003;285(4):C723–34
   Google Scholar
• Gu X, Zhang W, Liu J, Shaw JP, Shen Y, Xu Y, Lu H, Wu Z. Preparation and characterization of a lovastatin-loaded protein-free nanostructured lipid carrier resembling high-density lipoprotein and evaluation of its targeting to foam cells. AAPS PharmSciTech, 2011;12(4):1200–8
   PubMed Web of Science ®Google Scholar
• Guterres FA, Martinez GR, Rocha ME, Winnischofer SM. Simvastatin rises reactive oxygen species levels and induces senescence in human melanoma cells by activation of p53/p21 pathway. Exp Cell Res, 2013;319(19):2977–88
   PubMed Web of Science ®Google Scholar
• Hanai J, Doro N, Sasaki AT, Kobayashi S, Cantley LC, Seth P, Sukhatme VP. Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways. J Cell Physiol, 2012;227(4):1709–20
   PubMed Web of Science ®Google Scholar
• Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev, 2004;18(18):2195–224
   PubMed Web of Science ®Google Scholar
• Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist, 2006;11(3):306–15
   PubMed Web of Science ®Google Scholar
• Ho MH, Chiang CP, Liu YF, Kuo MY, Lin SK, Lai JY, Lee BS. Highly efficient release of lovastatin from poly(lactic-co-glycolic acid) nanoparticles enhances bone repair in rats. J Orthop Res, 2011;29(10):1504–10
   PubMed Web of Science ®Google Scholar
• Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev, 2008;17(1):88–94
   PubMed Web of Science ®Google Scholar
• Horiguchi A, Sumitomo M, Asakuma J, Asano T, Hayakawa M. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res, 2004;10(24):8648–55
   PubMed Web of Science ®Google Scholar
• Huerta S, Chilka S, Bonavida B. Nitric oxide donors: Novel cancer therapeutics (review). Int J Oncol, 2008;33(5):909–27
   PubMed Web of Science ®Google Scholar
• Hussain SP, Harris CC. Inflammation and cancer: An ancient link with novel potentials. Int J Cancer, 2007;121(11):2373–80
   PubMed Web of Science ®Google Scholar
• Hwang KE, Na KS, Park DS, Choi KH, Kim BR, Shim H, Jeong ET, Kim HR. Apoptotic induction by simvastatin in human lung cancer A549 cells via Akt signaling dependent down-regulation of survivin. Invest New Drugs, 2010;29(5):945–52
   PubMed Web of Science ®Google Scholar
• Ishikawa S, Hayashi H, Kinoshita K, Abe M, Kuroki H, Tokunaga R, Tomiyasu S, Tanaka H, Sugita H, Arita T, et al. Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer. Int J Cancer, 2014;135(11):2528–36
   PubMed Web of Science ®Google Scholar
• Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science, 2001;292(5519):1160–4
   PubMed Web of Science ®Google Scholar
• Jakobisiak M, Bruno S, Skierski JS, Darzynkiewicz Z. Cell cycle-specific effects of lovastatin. Proc Natl Acad Sci USA, 1991;88(9):3628–32
   PubMed Web of Science ®Google Scholar
• Jakobisiak M, Golab J. Potential antitumor effects of statins (Review). Int J Oncol, 2003;23(4):1055–69
   PubMed Web of Science ®Google Scholar
• Jiang T, Han N, Zhao B, Xie Y, Wang S. Enhanced dissolution rate and oral bioavailability of simvastatin nanocrystal prepared by sonoprecipitation. Drug Dev Ind Pharm, 2012;38(10):1230–9
   PubMed Web of Science ®Google Scholar
• Jones MK, Itani RM, Wang H, Tomikawa M, Sarfeh IJ, Szabo S, Tarnawski AS. Activation of VEGF and Ras genes in gastric mucosa during angiogenic response to ethanol injury. Am J Physiol, 1999;276(6 Pt 1):G1345–55
   PubMedGoogle Scholar
• Kah J, Wustenberg A, Keller AD, Sirma H, Montalbano R, Ocker M, Volz T, Dandri M, Tiegs G, Sass G. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep, 2012;28(3):1077–83
   PubMed Web of Science ®Google Scholar
• Kamat AM, Nelkin GM. Atorvastatin: A potential chemopreventive agent in bladder cancer. Urology, 2005;66(6):1209–12
   PubMed Web of Science ®Google Scholar
• Kanjoormana AM, Shanmugam MK, Feng L, Luxi C, Kodappully SS, Seok AK, PremKumar A, Gautam S. Simvastatin sensitises human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products. J Mol Med, 2014;92(3):267–76
   PubMed Web of Science ®Google Scholar
• Kanugula AK, Gollavilli PN, Vasamsetti SB, Karnewar S, Gopoju R, Ummanni R, Kotamraju S. Statin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: Intermediacy of nitric oxide and antioxidant defence mechanisms. FEBS J, 2014;281(16):3719–38
   PubMed Web of Science ®Google Scholar
• Kato S, Smalley S, Sadarangani A, Chen-Lin K, Oliva B, Branes J, Carvajal J, Gejman R, Owen GI, Cuello M. Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase. J Cell Mol Med, 2010;14(5):1180–93
   PubMed Web of Science ®Google Scholar
• Katz MS. Therapy insight: Potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol, 2005;2(2):82–9
   PubMedGoogle Scholar
• Khanzada UK, Pardo OE, Meier C, Downward J, Seckl MJ, Arcaro A. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene, 2006;25(6):877–87
   PubMed Web of Science ®Google Scholar
• Kidera Y, Tsubaki M, Yamazoe Y, Shoji K, Nakamura H, Ogaki M, Satou T, Itoh T, Isozaki M, Kaneko J, et al. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway. J Exp Clin Cancer Res, 2010;29:127
   PubMedGoogle Scholar
• Kim MS, Jin SJ, Kim JS, Park HJ, Song HS, Neubert RH, Hwang SJ. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process. Eur J Pharm Biopharm, 2008;69(2):454–65
   PubMed Web of Science ®Google Scholar
• Kodach LL, Bleuming SA, Peppelenbosch MP, Hommes DW, van den Brink GR, Hardwick JC. The effect of statins in colorectal cancer is mediated through the bone morphogenetic protein pathway. Gastroenterology, 2007;133(4):1272–81
   PubMed Web of Science ®Google Scholar
• Koga T, Shimada Y, Kuroda M, Tsujita Y, Hasegawa K, Yamazaki M. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta, 1990;1045(2):115–20
   PubMed Web of Science ®Google Scholar
• Kotamraju S, Williams CL, Kalyanaraman B. Statin-induced breast cancer cell death: Role of inducible nitric oxide and arginase-dependent pathways. Cancer Res, 2007;67(15):7386–94
   PubMed Web of Science ®Google Scholar
• Koyuturk M, Ersoz M, Altiok N. Simvastatin induces proliferation inhibition and apoptosis in C6 glioma cells via c-jun N-terminal kinase. Neurosci Lett, 2004;370(2–3):212–17
   PubMed Web of Science ®Google Scholar
• Koyuturk M, Ersoz M, Altiok N. Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen receptor independent pathway requiring signalling through JNK. Cancer Lett, 2007;250(2):220–8
   PubMed Web of Science ®Google Scholar
• Kubo M, Egashira K, Inoue T, Koga J, Oda S, Chen L, Nakano K, Matoba T, Kawashima Y, Hara K, et al. Therapeutic neovascularization by nanotechnology-mediated cell-selective delivery of pitavastatin into the vascular endothelium. Arterioscler Thromb Vasc Biol, 2009;29(6):796–801
   PubMed Web of Science ®Google Scholar
• Kumar P, Ghosh A, M MC. Stability indicating method development for simultaneous estimation of ezetimibe and atorvastatin in pharmaceutical formulations by RP-HPLC. Pharmaceut Anal Acta, 2012;3:164
   Google Scholar
• Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Inoue M, Nakamura H. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology, 2002;122(2):308–17
   PubMed Web of Science ®Google Scholar
• Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Nakamura H. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors. Cancer Res, 2001;61(12):4885–91
   PubMed Web of Science ®Google Scholar
• Laezza C, Fiorentino L, Pisanti S, Gazzerro P, Caraglia M, Portella G, Vitale M, Bifulco M. Lovastatin induces apoptosis of k-ras-transformed thyroid cells via inhibition of ras farnesylation and by modulating redox state. J Mol Med (Berl), 2008;86(12):1341–51
   PubMed Web of Science ®Google Scholar
• Lasic DD. Mixed micelles in drug delivery. Nature, 1992;355(6357):279–80
   PubMed Web of Science ®Google Scholar
• Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst, 2011;103(8):674–88
   PubMed Web of Science ®Google Scholar
• Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet, 1997;32(5):403–25
   PubMed Web of Science ®Google Scholar
• Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest, 2002;110(3):285–8
   PubMed Web of Science ®Google Scholar
• Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol, 2005;45:89–118
   PubMed Web of Science ®Google Scholar
• Liu F, Park JY, Zhang Y, Conwell C, Liu Y, Bathula SR, Huang L. Targeted cancer therapy with novel high drug-loading nanocrystals. J Pharm Sci, 2010;99(8):3542–51
   PubMed Web of Science ®Google Scholar
• Liu H, Liang SL, Kumar S, Weyman CM, Liu W, Zhou A. Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression. Cancer Chemother Pharmacol, 2009;63(6):997–1005
   PubMed Web of Science ®Google Scholar
• Liu X, Li X, Zhou L, Li S, Sun J, Wang Z, Gao Y, Jiang Y, Lu H, Wang Q, Dai J. Effects of simvastatin-loaded polymeric micelles on human osteoblast-like MG-63 cells. Colloids Surf B Biointerfaces, 2013;102:420–7
   PubMed Web of Science ®Google Scholar
• Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X, Dai H. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res, 2008;68(16):6652–60
   PubMed Web of Science ®Google Scholar
• Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release, 2001;74(1–3):47–61
   PubMed Web of Science ®Google Scholar
• Maksimova E, Yie TA, Rom WN. In vitro mechanisms of lovastatin on lung cancer cell lines as a potential chemopreventive agent. Lung, 2008;186(1):45–54
   PubMed Web of Science ®Google Scholar
• Maltese WA, Sheridan KM. Differentiation of neuroblastoma cells induced by an inhibitor of mevalonate synthesis: Relation of neurite outgrowth and acetylcholinesterase activity to changes in cell proliferation and blocked isoprenoid synthesis. J Cell Physiol, 1985;125(3):540–58
   PubMed Web of Science ®Google Scholar
• Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev, 2006;25(3):315–22
   PubMed Web of Science ®Google Scholar
• Marcelli M, Cunningham GR, Haidacher SJ, Padayatty SJ, Sturgis L, Kagan C, Denner L. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res, 1998;58(1):76–83
   PubMed Web of Science ®Google Scholar
• Martins SM, Sarmento B, Nunes C, Lucio M, Reis S, Ferreira DC. Brain targeting effect of camptothecin-loaded solid lipid nanoparticles in rat after intravenous administration. Eur J Pharm Biopharm, 2013;85(3 Pt A):488–502
   PubMed Web of Science ®Google Scholar
• Martirosyan A, Clendening JW, Goard CA, Penn LZ. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: Potential therapeutic relevance. BMC Cancer, 2010;10:103
   PubMed Web of Science ®Google Scholar
• Matsuura M, Suzuki T, Suzuki M, Tanaka R, Ito E, Saito T. Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol Rep, 2010;25(1):41–7
   Web of Science ®Google Scholar
• McInnes IB, Leung BP, Liew FY. Cell-cell interactions in synovitis. Interactions between T lymphocytes and synovial cells. Arthritis Res, 2000;2(5):374–8
   Web of Science ®Google Scholar
• Mehta N, Hordines J, Sykes D, Doerr RJ, Cohen SA. Low density lipoproteins and Lovastatin modulate the organ-specific transendothelial migration of primary and metastatic human colon adenocarcinoma cell lines in vitro. Clin Exp Metastasis, 1998;16(7):587–94
   PubMed Web of Science ®Google Scholar
• Mekhail GM, Kamel AO, Awad GA, Mortada ND. Anticancer effect of atorvastatin nanostructured polymeric micelles based on stearyl-grafted chitosan. Int J Biol Macromol, 2012;51(4):351–63
   PubMed Web of Science ®Google Scholar
• Menter DG, Ramsauer VP, Harirforoosh S, Chakraborty K, Yang P, Hsi L, Newman RA, Krishnan K. Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PLoS One, 2011;6(12):e28813
   PubMed Web of Science ®Google Scholar
• Mills CN, Joshi SS, Niles RM. Expression and function of hypoxia inducible factor-1 alpha in human melanoma under non-hypoxic conditions. Mol Cancer, 2009;8:104
   PubMed Web of Science ®Google Scholar
• Minichsdorfer C, Hohenegger M. Autocrine amplification loop in statin-induced apoptosis of human melanoma cells. Br J Pharmacol, 2009;157(7):1278–90
   PubMed Web of Science ®Google Scholar
• Mira E, Carmona-Rodriguez L, Tardaguila M, Azcoitia I, Gonzalez-Martin A, Almonacid L, Casas J, Fabrias G, Manes S. A lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumors. Oncotarget, 2013;4(12):2288–301
   PubMedGoogle Scholar
• Moriceau G, Roelofs AJ, Brion R, Redini F, Ebetion FH, Rogers MJ, Heymann D. Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth. Cancer, 2011;118(3):750–60
   PubMed Web of Science ®Google Scholar
• Murtola TJ, Syvala H, Pennanen P, Blauer M, Solakivi T, Ylikomi T, Tammela TL. Comparative effects of high and low-dose simvastatin on prostate epithelial cells: The role of LDL. Eur J Pharmacol, 2011;673(1–3):96–100
   PubMed Web of Science ®Google Scholar
• Nubel T, Dippold W, Kleinert H, Kaina B, Fritz G. Lovastatin inhibits Rho-regulated expression of E-selectin by TNFalpha and attenuates tumor cell adhesion. FASEB J, 2004;18(1):140–2
   PubMed Web of Science ®Google Scholar
• Osmak M. Statins and cancer: Current and future prospects. Cancer Lett, 2012;324(1):1–12
   PubMed Web of Science ®Google Scholar
• Padhye SG, Nagarsenker MS. Simvastatin solid lipid nanoparticles for oral delivery: Formulation development and in vivo evaluation. Indian J Pharm Sci, 2014;75(5):591–8
   Web of Science ®Google Scholar
• Park C, Lee I, Kang WK. Lovastatin-induced E2F-1 modulation and its effect on prostate cancer cell death. Carcinogenesis, 2001;22(10):1727–31
   PubMed Web of Science ®Google Scholar
• Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res, 2002;91(2):143–50
   PubMed Web of Science ®Google Scholar
• Park IH, Kim JY, Jung JI, Han JY. Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations. Invest New Drugs, 2010;28(6):791–9
   PubMed Web of Science ®Google Scholar
• Park YH, Seo SY, Lee E, Ku JH, Kim HH, Kwak C. Simvastatin induces apoptosis in castrate resistant prostate cancer cells by deregulating nuclear factor-kappaB pathway. J Urol, 2013;189:1547–52
   PubMed Web of Science ®Google Scholar
• Pelaia G, Gallelli L, Renda T, Fratto D, Falcone D, Caraglia M, Busceti MT, Terracciano R, Vatrella A, Maselli R, Savino R. Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells. Cell Prolif, 2012;45(6):557–65
   PubMed Web of Science ®Google Scholar
• Pich C, Teiti I, Rochaix P, Mariame B, Couderc B, Favre G, Tilkin-Mariame AF. Statins reduce melanoma development and metastasis through MICA overexpression. Front Immunol, 2013;4:62
   Google Scholar
• Pisanti S, Picardi P, Ciaglia E, D'Alessandro A, Bifulco M. Novel prospects of statins as therapeutic agents in cancer. Pharmacol Res, 2014;88:84–98
   PubMed Web of Science ®Google Scholar
• Porfire A, Tomuta I, Muntean D, Luca L, Licarete E, Alupei MC, Achim M, Vlase L, Banciu M. Optimizing long-circulating liposomes for delivery of simvastatin to C26 colon carcinoma cells. J Liposome Res, 2014 . [Epub ahead of print]. doi: 10.3109/08982104.2014.987787
   PubMedGoogle Scholar
• Prendergast GC, Khosravi-Far R, Solski PA, Kurzawa H, Lebowitz PF, Der CJ. Critical role of Rho in cell transformation by oncogenic Ras. Oncogene, 1995;10(12):2289–96
   PubMed Web of Science ®Google Scholar
• Qi XF, Kim DH, Yoon YS, Kim SK, Cai DQ, Teng YC, Shim KY, Lee KJ. Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells. Toxicol Lett, 2010;199(3):277–87
   PubMed Web of Science ®Google Scholar
• Qi XF, Zheng L, Lee KJ, Kim DH, Kim CS, Cai DQ, Wu Z, Qin JW, Yu YH, Kim SK. HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death Dis, 2013;4:e518
   PubMed Web of Science ®Google Scholar
• Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci USA, 1999;96(14):7797–802
   PubMed Web of Science ®Google Scholar
• Rastogi V, Yadav P, Bhattacharya SS, Mishra AK, Verma N, Verma A, Pandit JK. Carbon nanotubes: An emerging drug carrier for targeting cancer cells. J Drug Deliv, 2014;2014:670815
   PubMedGoogle Scholar
• Relja B, Meder F, Wang M, Blaheta R, Henrich D, Marzi I, Lehnert M. Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK. Int J Oncol, 2011;38(3):879–85
   PubMed Web of Science ®Google Scholar
• Relja B, Meder F, Wilhelm K, Henrich D, Marzi I, Lehnert M. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med, 2010;26(5):735–41
   PubMed Web of Science ®Google Scholar
• Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med, 2010;49(11):1603–16
   PubMed Web of Science ®Google Scholar
• Ridnour LA, Thomas DD, Switzer C, Flores-Santana W, Isenberg JS, Ambs S, Roberts DD, Wink DA. Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide, 2008;19(2):73–6
   PubMed Web of Science ®Google Scholar
• Riganti C, Pinto H, Bolli E, Belisario DC, Calogero RA, Bosia A, Cavallo F. Atorvastatin modulates anti-proliferative and pro-proliferative signals in Her2/neu-positive mammary cancer. Biochem Pharmacol, 2011;82(9):1079–89
   PubMed Web of Science ®Google Scholar
• Robinson E, Nandi M, Wilkinson LL, Arrowsmith DM, Curtis AD, Richardson A. Preclinical evaluation of statins as a treatment for ovarian cancer. Gynecol Oncol, 2013;129:417–24
   PubMed Web of Science ®Google Scholar
• Romana B, Batger M, Prestidge CA, Colombo G, Sonvico F. Expanding the therapeutic potential of statins by means of nanotechnology enabled drug delivery systems. Curr Top Med Chem, 2014;14(9):1182–93
   PubMed Web of Science ®Google Scholar
• Sadaria MR, Reppert AE, Yu JA, Meng X, Fullerton DA, Reece TB, Weyant MJ. Statin therapy attenuates growth and malignant potential of human esophageal adenocarcinoma cells. J Thorac Cardiovasc Surg, 2011;142(5):1152–60
   PubMed Web of Science ®Google Scholar
• Sahoo NG, Bao H, Pan Y, Pal M, Kakran M, Cheng HK, Li L, Tan LP. Functionalised carbon nanomaterials as nanocarriers for loading and delivery of a poorly water-soluble anticancer drug: A comparative study. Chem Commun (Camb), 2011;47(18):5235–7
   PubMed Web of Science ®Google Scholar
• Sanchez CA, Rodriguez E, Varela E, Zapata E, Paez A, Masso FA, Montano LF, Loopez-Marure R. Statin-induced inhibition of MCF-7 breast cancer cell proliferation is related to cell cycle arrest and apoptotic and necrotic cell death mediated by an enhanced oxidative stress. Cancer Invest, 2008;26(7):698–707
   PubMed Web of Science ®Google Scholar
• Sandoval-Usme MC, Umana-Perez A, Guerra B, Hernandez-Perera O, Garcia-Castellano JM, Fernandez-Perez L, Sanchez-Gomez M. Simvastatin impairs growth hormone-activated signal transducer and activator of transcription (STAT) signaling pathway in UMR-106 osteosarcoma cells. PLoS One, 2014;9(1):e87769
   Google Scholar
• Sassano A, Katsoulidis E, Antico G, Altman JK, Redig AJ, Minucci S, Tallman MS, Platanias LC. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res, 2007;67(9):4524–32
   PubMed Web of Science ®Google Scholar
• Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam Clin Pharmacol, 2005;19(1):117–25
   PubMed Web of Science ®Google Scholar
• Schointuch MN, Gilliam TP, Stine JE, Han X, Zhou C, Gehrig PA, Kim K, Bae-Jump VL. Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer. Gynecol Oncol, 2014;134(2):346–55
   PubMed Web of Science ®Google Scholar
• Schumacker PT. Reactive oxygen species in cancer cells: Live by the sword, die by the sword. Cancer Cell, 2006;10(3):175–6
   PubMed Web of Science ®Google Scholar
• Shah M, Chuttani K, Mishra AK, Pathak K. Oral solid compritol 888 ATO nanosuspension of simvastatin: Optimization and biodistribution studies. Drug Dev Ind Pharm, 2011;37(5):526–37
   PubMed Web of Science ®Google Scholar
• Shah M, Pathak K. Development and statistical optimization of solid lipid nanoparticles of simvastatin by using 2(3) full-factorial design. AAPS PharmSciTech, 2010;11(2):489–96
   PubMed Web of Science ®Google Scholar
• Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene, 2001;20(19):2390–400
   PubMed Web of Science ®Google Scholar
• Shellman YG, Ribble D, Miller L, Gendall J, Vanbuskirk K, Kelly D, Norris DA, Dellavalle RP. Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res, 2005;15(2):83–9
   PubMed Web of Science ®Google Scholar
• Shenoy VS, Vijay IK, Murthy RS. Tumour targeting: Biological factors and formulation advances in injectable lipid nanoparticles. J Pharm Pharmacol, 2005;57(4):411–22
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995;333(20):1301–7
   PubMed Web of Science ®Google Scholar
• Shibata MA, Ito Y, Morimoto J, Otsuki Y. Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: A p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis, 2004;25(10):1887–98
   PubMed Web of Science ®Google Scholar
• Simsek S, Eroglu H, Kurum B, Ulubayram K. Brain targeting of Atorvastatin loaded amphiphilic PLGA-b-PEG nanoparticles. J Microencapsul, 2013;30(1):10–20
   PubMed Web of Science ®Google Scholar
• Skottheim IB, Gedde-Dahl A, Hejazifar S, Hoel K, Asberg A. Statin induced myotoxicity: The lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro. Eur J Pharm Sci, 2008;33(4–5):317–25
   PubMed Web of Science ®Google Scholar
• Song X, Liu BC, Lu XY, Yang LL, Zhai YJ, Eaton AF, Thai TL, Eaton DC, Ma HP, Shen BZ. Lovastatin inhibits human B lymphoma cell proliferation by reducing intracellular ROS and TRPC6 expression. Biochim Biophys Acta, 2014;1843(5):894–901
   PubMed Web of Science ®Google Scholar
• Soni A, Gadad A, Dandag P, Mastiholimath V. Simvastatin-loaded PLGA nanoparticles for improved oral bioavailability and sustained release: Effect of formulation variables. Asian J Pharm, 2011;5:57–64
   Google Scholar
• Spampanato C, De Maria S, Sarnataro M, Giordano E, Zanfardino M, Baiano S, Carteni M, Morelli F. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. Int J Oncol, 2011;40(4):935–41
   PubMed Web of Science ®Google Scholar
• Sripriyalakshmi S, Anjali CH, George PD, Rajith B, Ravindran A. BSA nanoparticle loaded atorvastatin calcium – a new facet for an old drug. PLoS One, 2014;9(2):e86317
   PubMed Web of Science ®Google Scholar
• Suresh G, Manjunath K, Venkateswarlu V, Satyanarayana V. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech, 2007;8(1):24
   PubMed Web of Science ®Google Scholar
• Sutter AP, Maaser K, Hopfner M, Huether A, Schuppan D, Scherubl H. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol, 2005;43(5):808–16
   Google Scholar
• Sylvester PW. Synergistic anticancer effects of combined gamma-tocotrienol with statin or receptor tyrosine kinase inhibitor treatment. Genes Nutr, 2011;7(1):63–74
   PubMed Web of Science ®Google Scholar
• Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, Kitakaze M, Liao JK. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest, 2001;108(10):1429–37
   PubMed Web of Science ®Google Scholar
• Tavintharan S, Ong CN, Jeyaseelan K, Sivakumar M, Lim SC, Sum CF. Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: A possible role in statin-induced hepatotoxicity? Toxicol Appl Pharmacol, 2007;223(2):173–9
   PubMed Web of Science ®Google Scholar
• Taylor-Harding B, Orsulic S, Karlan BY, Li AJ. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. Gynecol Oncol, 2010;119(3):549–56
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Lukyanov AN, Gao Z, Papahadjopoulos-Sternberg B. Immunomicelles: Targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci USA, 2003;100(10):6039–44
   PubMed Web of Science ®Google Scholar
• Tu YS, Kang XL, Zhou JG, Lv XF, Tang YB, Guan YY. Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in simvastatin induced S-phase cell cycle arrest and apoptosis in multiple myeloma cells. Eur J Pharmacol, 2011;670(2–3):356–64
   PubMed Web of Science ®Google Scholar
• Ukomadu C, Dutta A. Inhibition of cdk2 activating phosphorylation by mevastatin. J Biol Chem, 2003a;278(7):4840–6
   PubMed Web of Science ®Google Scholar
• Ukomadu C, Dutta A. p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases. J Biol Chem, 2003b;278(44):43586–94
   PubMed Web of Science ®Google Scholar
• Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett, 2008;582(14):2093–101
   PubMed Web of Science ®Google Scholar
• Vidal A, Millard SS, Miller JP, Koff A. Rho activity can alter the translation of p27 mRNA and is important for RasV12-induced transformation in a manner dependent on p27 status. J Biol Chem, 2002;277(19):16433–40
   PubMed Web of Science ®Google Scholar
• Wachtershauser A, Akoglu B, Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis, 2001;22(7):1061–7
   PubMed Web of Science ®Google Scholar
• Wang CY, Shui HA, Chang TC. In vivo evidence of duality effects for lovastatin in a nude mouse cancer model. Int J Cancer, 2010;126(2):578–82
   PubMed Web of Science ®Google Scholar
• Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by lovastatin through activation of caspase-3 and DNase II in leukaemia HL-60 cells. Pharmacol Toxicol, 2000a;86(2):83–91
   PubMedGoogle Scholar
• Wang IK, Lin-Shiau SY, Lin JK. Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation. Oncology, 2000b;59(3):245–54
   PubMed Web of Science ®Google Scholar
• Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, Itter G, Rosen R, Bohm M, Nickenig G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension, 2001;37(6):1450–7
   PubMed Web of Science ®Google Scholar
• Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation, 2002;105(6):739–45
   PubMed Web of Science ®Google Scholar
• Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apoptosis. Leukemia, 2002;16(4):508–19
   PubMed Web of Science ®Google Scholar
• Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD, Penn LZ. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res, 2001;7(7):2067–75
   PubMed Web of Science ®Google Scholar
• Woodard J, Sassano A, Hay N, Platanias LC. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma. Clin Cancer Res, 2008;14(14):4640–9
   PubMed Web of Science ®Google Scholar
• Wu Y, Antony S, Meitzler JL, Doroshow JH. Molecular mechanisms underlying chronic inflammation-associated cancers. Cancer Lett, 2013;345(2):164–73
   PubMed Web of Science ®Google Scholar
• Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia, 2001;15(9):1398–407
   PubMed Web of Science ®Google Scholar
• Xiao H, Zhang Q, Lin Y, Reddy BS, Yang CS. Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer, 2008;122(9):2115–24
   PubMed Web of Science ®Google Scholar
• Xu P, Yu H, Zhang Z, Meng Q, Sun H, Chen X, Yin Q, Li Y. Hydrogen-bonded and reduction-responsive micelles loading atorvastatin for therapy of breast cancer metastasis. Biomaterials, 2014;35(26):7574–87
   PubMed Web of Science ®Google Scholar
• Yajima I, Kumasaka MY, Thang ND, Goto Y, Takeda K, Yamanoshita O, Iida M, Ohgami N, Tamura H, Kawamoto Y, Kato M. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy. Dermatol Res Pract, 2011;2012:354191
   PubMedGoogle Scholar
• Yanae M, Tsubaki M, Satou T, Itoh T, Imano M, Yamazoe Y, Nishida S. Statin-induced apoptosis via the suppression of ERK1/2 and Akt activation by inhibition of the geranylgeranyl-pyrophosphate biosynthesis in glioblastoma. J Exp Clin Cancer Res, 2011;30:74
   PubMed Web of Science ®Google Scholar
• Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release, 1999;59(3):299–307
   PubMed Web of Science ®Google Scholar
• Yang Z, Kozai T, van der Loo B, Viswambharan H, Lachat M, Turina MI, Malinski T, Luscher TF. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol, 2000;36(5):1691–7
   PubMed Web of Science ®Google Scholar
• Ye F, Zhang GH, Guan BX, Xu XC. Suppression of esophageal cancer cell growth using curcumin, (-)-epigallocatechin-3-gallate and lovastatin. World J Gastroenterol, 2012;18(2):126–35
   PubMed Web of Science ®Google Scholar
• Yeganeh B, Wiechec E, Ande SR, Sharma P, Moghadam AR, Post M, Freed DH, Hashemi M, Shojaei S, Zeki AA, Ghavami S. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol Ther, 2014;143(1):87–110
   PubMed Web of Science ®Google Scholar
• Yongjun Y, Shuyun H, Lei C, Xiangrong C, Zhilin Y, Yiquan K. Atorvastatin suppresses glioma invasion and migration by reducing microglial MT1-MMP expression. J Neuroimmunol, 2013;260(1–2):1–8
   PubMed Web of Science ®Google Scholar
• Yu X, Pan Y, Ma H, Li W. Simvastatin inhibits proliferation and induces apoptosis in human lung cancer cells. Oncol Res, 2013;20(8):351–7
   PubMed Web of Science ®Google Scholar
• Zeidooni L, Rezaei M, Hashemi Tabar M. Gamma tocopherol and lovastatin additively induced apoptosis in human colorectal carcinoma cell line (HT29). Jundishapur J Nat Pharm Prod, 2012;7(4):153–8
   Google Scholar
• Zeybek ND, Gulcelik NE, Kaymaz FF, Sarisozen C, Vural I, Bodur E, Canpinar H, Usman A, Asan E. Rosuvastatin induces apoptosis in cultured human papillary thyroid cancer cells. J Endocrinol, 2011;210(1):105–15
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang Z, Xie L, Xu L, Xu D, Liu X. Statins, autophagy and cancer metastasis. Int J Biochem Cell Biol, 2013;45(3):745–52
   PubMed Web of Science ®Google Scholar
• Zhang S, Doudican NA, Quay E, Orlow SJ. Fluvastatin enhances sorafenib cytotoxicity in melanoma cells via modulation of AKT and JNK signaling pathways. Anticancer Res, 2011;31(10):3259–65
   PubMed Web of Science ®Google Scholar
• Zhang W, Wu J, Zhou L, Xie HY, Zheng SS. Fluvastatin, a lipophilic statin, induces apoptosis in human hepatocellular carcinoma cells through mitochondria-operated pathway. Indian J Exp Biol, 2010;48(12):1167–74
   PubMed Web of Science ®Google Scholar
• Zhong WB, Liang YC, Wang CY, Chang TC, Lee WS. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Endocr Relat Cancer, 2005;12(3):615–29
   PubMed Web of Science ®Google Scholar
• Zhong WB, Wang CY, Chang TC, Lee WS. Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology, 2003;144(9):3852–9
   PubMed Web of Science ®Google Scholar
• Zhu Y, Casey PJ, Kumar AP, Pervaiz S. Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: Evidence for non-canonical activation of RhoA and Rac1 GTPases. Cell Death Dis, 2013;4:e568
   PubMed Web of Science ®Google Scholar
• Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest, 2005;115(4):959–68
   PubMed Web of Science ®Google Scholar